ArticleIn vivo (Athens, Greece)
Evaluation of Altered Myocardial Blood Flow and Cardiovascular Function in Patients With Thyroid Cancer and Related Treatments.
Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Integrative Cross-platform Analysis of Kinase Inhibitor Effects on Statin-relevant Cardioprotective Pathways in Human Cardiomyocytes.Cancer genomics & proteomicsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimThis study aimed to explore changes in cardiovascular performance among patients with thyroid cancer following thyroidectomy, radioiodine therapy (RAIT) and thyroid-stimulating hormone suppression therapy (TST), with or without treatment with tyrosine kinase inhibitors (TKIs). PATIENTS AND
methodsWe enrolled 32 patients who underwent thyroidectomy and subsequent RAIT (except for one patient who underwent partial thyroidectomy only) and TST, with or without TKI therapy. We assessed myocardial perfusion using quantitative myocardial perfusion imaging (qMPI), myocardial blood flow (MBF), and coronary flow reserve (CFR)
resultsqMPI indicated that the TKI-treated group (n=19) exhibited reduced MBF, CFR, and coronary flow capacity compared to the non-TKI-treated group. The right coronary artery (RCA) territory was notably affected by TKI treatment, particularly during the stress phase: RCA-stress blood flow: 2.4±0.6
conclusionTKI therapy, especially anti-vascular endothelial growth factor TKI, can negatively affect myocardial perfusion and lead to coronary microcirculation dysfunction, reducing MBF/CFR during the stress phase. The link between cumulative RAIT dose, lower thyroid-stimulating hormone level, and abnormal MBF/CFR highlights the need for further research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.